 Cancer vaccines are designed to stimulate the immune system to kill tumor cells by combining antigens with adjuvants that mimic natural microbial ligands and have been extensively explored as vaccine adjuvants, but their approval for clinical use is still pending. This article was authored by Luisa Cercelli, Maria Lina Tornicello, Franco M. Buonaguro, and others.